Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 471

1.

Tenascin C regulates multiple microglial functions involving TLR4 signaling and HDAC1.

Haage V, Elmadany N, Roll L, Faissner A, Gutmann DH, Semtner M, Kettenmann H.

Brain Behav Immun. 2019 Jul 2. pii: S0889-1591(19)30465-9. doi: 10.1016/j.bbi.2019.06.047. [Epub ahead of print]

2.

Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 May 31. doi: 10.1038/s41571-019-0236-y. [Epub ahead of print] No abstract available.

PMID:
31150022
3.

Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia.

Guo X, Pan Y, Gutmann DH.

Neuro Oncol. 2019 May 3. pii: noz080. doi: 10.1093/neuonc/noz080. [Epub ahead of print]

PMID:
31111915
4.

Commentary: Identification of Mutation Regions on NF1 Responsible for High- and Low-Risk Development of Optic Pathway Glioma in Neurofibromatosis Type I.

Anastasaki C, Gao F, Gutmann DH.

Front Genet. 2019 Mar 1;10:115. doi: 10.3389/fgene.2019.00115. eCollection 2019. No abstract available.

5.

Comprehensive gene expression meta-analysis identifies signature genes that distinguish microglia from peripheral monocytes/macrophages in health and glioma.

Haage V, Semtner M, Vidal RO, Hernandez DP, Pong WW, Chen Z, Hambardzumyan D, Magrini V, Ly A, Walker J, Mardis E, Mertins P, Sauer S, Kettenmann H, Gutmann DH.

Acta Neuropathol Commun. 2019 Feb 14;7(1):20. doi: 10.1186/s40478-019-0665-y.

6.

Challenges to curing primary brain tumours.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 Feb 7. doi: 10.1038/s41571-019-0177-5. [Epub ahead of print] Review.

PMID:
30733593
7.

Adaptive functioning in children with neurofibromatosis type 1: relationship to cognition, behavior, and magnetic resonance imaging.

Eby NS, Griffith JL, Gutmann DH, Morris SM.

Dev Med Child Neurol. 2019 Aug;61(8):972-978. doi: 10.1111/dmcn.14144. Epub 2019 Jan 18.

PMID:
30659594
8.

Clearing the Fog surrounding Chemobrain.

Gutmann DH.

Cell. 2019 Jan 10;176(1-2):2-4. doi: 10.1016/j.cell.2018.12.027.

PMID:
30633904
9.

Neurofibromatosis type 1 (Nf1)-mutant mice exhibit increased sleep fragmentation.

Anastasaki C, Rensing N, Johnson KJ, Wong M, Gutmann DH.

J Sleep Res. 2019 Aug;28(4):e12816. doi: 10.1111/jsr.12816. Epub 2019 Jan 4.

PMID:
30609083
10.

KIAA1549-BRAF Expression Establishes a Permissive Tumor Microenvironment Through NFκB-Mediated CCL2 Production.

Chen R, Keoni C, Waker CA, Lober RM, Chen YH, Gutmann DH.

Neoplasia. 2019 Jan;21(1):52-60. doi: 10.1016/j.neo.2018.11.007. Epub 2018 Nov 30.

11.

Variability of Betweenness Centrality and Its Effect on Identifying Essential Genes.

Durón C, Pan Y, Gutmann DH, Hardin J, Radunskaya A.

Bull Math Biol. 2018 Oct 22. doi: 10.1007/s11538-018-0526-z. [Epub ahead of print]

PMID:
30350013
12.

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1.

Isakson SH, Rizzardi AE, Coutts AW, Carlson DF, Kirstein MN, Fisher J, Vitte J, Williams KB, Pluhar GE, Dahiya S, Widemann BC, Dombi E, Rizvi T, Ratner N, Messiaen L, Stemmer-Rachamimov AO, Fahrenkrug SC, Gutmann DH, Giovannini M, Moertel CL, Largaespada DA, Watson AL.

Commun Biol. 2018 Oct 2;1:158. doi: 10.1038/s42003-018-0163-y. eCollection 2018.

13.

Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1.

Griffith JL, Morris SM, Mahdi J, Goyal MS, Hershey T, Gutmann DH.

Neurol Clin Pract. 2018 Aug;8(4):283-291. doi: 10.1212/CPJ.0000000000000494.

PMID:
30140579
14.

Independent NF1 mutations underlie café-au-lait macule development in a woman with segmental NF1.

Freret ME, Anastasaki C, Gutmann DH.

Neurol Genet. 2018 Jul 23;4(4):e261. doi: 10.1212/NXG.0000000000000261. eCollection 2018 Aug. No abstract available.

15.

Height Growth Impairment in Children With Neurofibromatosis Type 1 Is Characterized by Decreased Pubertal Growth Velocity in Both Sexes.

Zessis NR, Gao F, Vadlamudi G, Gutmann DH, Hollander AS.

J Child Neurol. 2018 Oct;33(12):762-766. doi: 10.1177/0883073818786807. Epub 2018 Jul 16.

PMID:
30009646
16.

Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.

Pan Y, Duron C, Bush EC, Ma Y, Sims PA, Gutmann DH, Radunskaya A, Hardin J.

PLoS One. 2018 May 22;13(5):e0190001. doi: 10.1371/journal.pone.0190001. eCollection 2018.

17.

Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.

Freret ME, Gutmann DH.

J Neurosci Res. 2019 Jan;97(1):45-56. doi: 10.1002/jnr.24250. Epub 2018 Apr 28. Review.

PMID:
29704429
18.

Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth.

Pan Y, Xiong M, Chen R, Ma Y, Corman C, Maricos M, Kindler U, Semtner M, Chen YH, Dahiya S, Gutmann DH.

Genes Dev. 2018 Apr 1;32(7-8):491-496. doi: 10.1101/gad.310797.117. Epub 2018 Apr 9.

19.

β-III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors.

Hirbe AC, Zhang X, Dahiya S, Godec A, Chrisinger J, Tao Y, Luo J, Gutmann DH.

Neuro Oncol. 2018 May 18;20(6):858-860. doi: 10.1093/neuonc/noy038. No abstract available.

20.

A Conserved Circadian Function for the Neurofibromatosis 1 Gene.

Bai L, Lee Y, Hsu CT, Williams JA, Cavanaugh D, Zheng X, Stein C, Haynes P, Wang H, Gutmann DH, Sehgal A.

Cell Rep. 2018 Mar 27;22(13):3416-3426. doi: 10.1016/j.celrep.2018.03.014.

21.

Neurofibromatosis type 1.

Cimino PJ, Gutmann DH.

Handb Clin Neurol. 2018;148:799-811. doi: 10.1016/B978-0-444-64076-5.00051-X. Review.

PMID:
29478615
22.

A genotype-phenotype correlation for quantitative autistic trait burden in neurofibromatosis 1.

Morris SM, Gutmann DH.

Neurology. 2018 Feb 20;90(8):377-379. doi: 10.1212/WNL.0000000000005000. Epub 2018 Jan 24. No abstract available.

PMID:
29367450
23.

Optic Pathway Gliomas in Neurofibromatosis Type 1.

Campen CJ, Gutmann DH.

J Child Neurol. 2018 Jan;33(1):73-81. doi: 10.1177/0883073817739509. Review.

24.

Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients.

Woodford MR, Sager RA, Marris E, Dunn DM, Blanden AR, Murphy RL, Rensing N, Shapiro O, Panaretou B, Prodromou C, Loh SN, Gutmann DH, Bourboulia D, Bratslavsky G, Wong M, Mollapour M.

EMBO J. 2017 Dec 15;36(24):3650-3665. doi: 10.15252/embj.201796700. Epub 2017 Nov 10.

25.

Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future.

Reilly KM, Kim A, Blakely J, Ferner RE, Gutmann DH, Legius E, Miettinen MM, Randall RL, Ratner N, Jumbé NL, Bakker A, Viskochil D, Widemann BC, Stewart DR.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx124. Review.

26.

Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights.

Khatua S, Gutmann DH, Packer RJ.

Pediatr Blood Cancer. 2018 Mar;65(3). doi: 10.1002/pbc.26838. Epub 2017 Oct 19. Review.

PMID:
29049847
27.

Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an age-dependent manner.

Zou J, Zhang B, Gutmann DH, Wong M.

Epilepsia. 2017 Dec;58(12):2053-2063. doi: 10.1111/epi.13923. Epub 2017 Oct 12.

28.

Children with 5'-end NF1 gene mutations are more likely to have glioma.

Anastasaki C, Morris SM, Gao F, Gutmann DH.

Neurol Genet. 2017 Sep 22;3(5):e192. doi: 10.1212/NXG.0000000000000192. eCollection 2017 Oct.

29.

Whole tumor RNA-sequencing and deconvolution reveal a clinically-prognostic PTEN/PI3K-regulated glioma transcriptional signature.

Pan Y, Bush EC, Toonen JA, Ma Y, Solga AC, Sims PA, Gutmann DH.

Oncotarget. 2017 Apr 18;8(32):52474-52487. doi: 10.18632/oncotarget.17193. eCollection 2017 Aug 8.

30.

Neurodevelopmental disorders in children with neurofibromatosis type 1.

Vogel AC, Gutmann DH, Morris SM.

Dev Med Child Neurol. 2017 Nov;59(11):1112-1116. doi: 10.1111/dmcn.13526. Epub 2017 Aug 27. Review.

31.

Characterization of early communicative behavior in mouse models of neurofibromatosis type 1.

Maloney SE, Chandler KC, Anastasaki C, Rieger MA, Gutmann DH, Dougherty JD.

Autism Res. 2018 Jan;11(1):44-58. doi: 10.1002/aur.1853. Epub 2017 Aug 26.

32.

The Tropism of Pleiotrophin: Orchestrating Glioma Brain Invasion.

Gutmann DH.

Cell. 2017 Aug 24;170(5):821-822. doi: 10.1016/j.cell.2017.08.011.

33.

Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, Avery RA.

J Neuroophthalmol. 2017 Sep;37 Suppl 1:S23-S32. doi: 10.1097/WNO.0000000000000550. Review.

PMID:
28806346
34.

Updated nomenclature for human and mouse neurofibromatosis type 1 genes.

Anastasaki C, Le LQ, Kesterson RA, Gutmann DH.

Neurol Genet. 2017 Jul 26;3(4):e169. doi: 10.1212/NXG.0000000000000169. eCollection 2017 Aug. No abstract available.

35.

The power of the few.

Chen R, Pan Y, Gutmann DH.

Genes Dev. 2017 Jun 15;31(12):1177-1179. doi: 10.1101/gad.303453.117. Review.

36.

CNS Tumors in Neurofibromatosis.

Campian J, Gutmann DH.

J Clin Oncol. 2017 Jul 20;35(21):2378-2385. doi: 10.1200/JCO.2016.71.7199. Epub 2017 Jun 22. Review.

37.

Caddyshack therapeutics: overcoming glioblastoma adaptation.

Gutmann DH.

Neuro Oncol. 2017 Oct 19;19(11):1429-1431. doi: 10.1093/neuonc/nox096. No abstract available.

38.

Oligodendroglial myelination requires astrocyte-derived lipids.

Camargo N, Goudriaan A, van Deijk AF, Otte WM, Brouwers JF, Lodder H, Gutmann DH, Nave KA, Dijkhuizen RM, Mansvelder HD, Chrast R, Smit AB, Verheijen MHG.

PLoS Biol. 2017 May 26;15(5):e1002605. doi: 10.1371/journal.pbio.1002605. eCollection 2017 May.

39.

KIR2DL5 mutation and loss underlies sporadic dermal neurofibroma pathogenesis and growth.

Anastasaki C, Dahiya S, Gutmann DH.

Oncotarget. 2017 Jul 18;8(29):47574-47585. doi: 10.18632/oncotarget.17736.

40.

The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.

Solga AC, Toonen JA, Pan Y, Cimino PJ, Ma Y, Castillon GA, Gianino SM, Ellisman MH, Lee DY, Gutmann DH.

Oncotarget. 2017 Jul 18;8(29):47206-47215. doi: 10.18632/oncotarget.17589.

41.

Using Epigenetic Reprogramming to Treat Pediatric Brain Cancer.

Chheda MG, Gutmann DH.

Cancer Cell. 2017 May 8;31(5):609-611. doi: 10.1016/j.ccell.2017.04.008.

42.

Increased Tissue Stiffness in Tumors from Mice with Neurofibromatosis-1 Optic Glioma.

Walter C, Crawford L, Lai M, Toonen JA, Pan Y, Sakiyama-Elbert S, Gutmann DH, Pathak A.

Biophys J. 2017 Apr 25;112(8):1535-1538. doi: 10.1016/j.bpj.2017.03.017.

43.

The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.

Blakeley JO, Bakker A, Barker A, Clapp W, Ferner R, Fisher MJ, Giovannini M, Gutmann DH, Karajannis MA, Kissil JL, Legius E, Lloyd AC, Packer RJ, Ramesh V, Riccardi VM, Stevenson DA, Ullrich NJ, Upadhyaya M, Stemmer-Rachamimov A.

Am J Med Genet A. 2017 Jun;173(6):1714-1721. doi: 10.1002/ajmg.a.38239. Epub 2017 Apr 24.

44.

MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models.

Hoye ML, Koval ED, Wegener AJ, Hyman TS, Yang C, O'Brien DR, Miller RL, Cole T, Schoch KM, Shen T, Kunikata T, Richard JP, Gutmann DH, Maragakis NJ, Kordasiewicz HB, Dougherty JD, Miller TM.

J Neurosci. 2017 May 31;37(22):5574-5586. doi: 10.1523/JNEUROSCI.3582-16.2017. Epub 2017 Apr 17.

45.

Human stem cell modeling in neurofibromatosis type 1 (NF1).

Wegscheid ML, Anastasaki C, Gutmann DH.

Exp Neurol. 2018 Jan;299(Pt B):270-280. doi: 10.1016/j.expneurol.2017.04.001. Epub 2017 Apr 6. Review.

46.

Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival.

Pan Y, Smithson LJ, Ma Y, Hambardzumyan D, Gutmann DH.

Oncotarget. 2017 May 16;8(20):32977-32989. doi: 10.18632/oncotarget.16516.

47.

A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1.

Mahdi J, Shah AC, Sato A, Morris SM, McKinstry RC, Listernick R, Packer RJ, Fisher MJ, Gutmann DH.

Neurology. 2017 Apr 18;88(16):1584-1589. doi: 10.1212/WNL.0000000000003881. Epub 2017 Mar 22.

48.

Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma.

Chen Z, Feng X, Herting CJ, Garcia VA, Nie K, Pong WW, Rasmussen R, Dwivedi B, Seby S, Wolf SA, Gutmann DH, Hambardzumyan D.

Cancer Res. 2017 May 1;77(9):2266-2278. doi: 10.1158/0008-5472.CAN-16-2310. Epub 2017 Feb 24.

49.

Neurofibromatosis type 1.

Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ.

Nat Rev Dis Primers. 2017 Feb 23;3:17004. doi: 10.1038/nrdp.2017.4. Review.

PMID:
28230061
50.

Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1.

Monroe CL, Dahiya S, Gutmann DH.

Annu Rev Pathol. 2017 Jan 24;12:53-74. doi: 10.1146/annurev-pathol-052016-100228. Review.

PMID:
28135565

Supplemental Content

Loading ...
Support Center